Nanotechnology Now - Press Release: Bio Nano Consulting (BNC) announces latest contract

Home > Press > Bio Nano Consulting (BNC) announces latest contract

Abstract:
BNC and Oxford Immunotec work together to improve infectious disease diagnosis and monitoring

Bio Nano Consulting (BNC) announces latest contract

London, UK | Posted on July 31st, 2008

Bio Nano Consulting (BNC), the specialist bionanotechnology product development consultancy, today announced that it has commenced a project with international T cell measurement company, Oxford Immunotec. BNC is applying its expertise in nano-characterisation to assist Oxford Immunotec in a project related to its novel Enzyme-Linked ImmunoSPOT (ELISPOT) system. As specialists in bio-nanotechnology, BNC is able to utilise the world-leading nano-characterisation facilities at the Institute of Biomedical Engineering, Imperial College London.

Oxford Immunotec is commercialising a diagnostic test to detect tuberculosis (TB) based on its patented T-SPOT technology, effectively providing a new way to diagnose and monitor this deadly disease. The World Health Organization (WHO) has estimated that almost 1.6 million deaths resulted worldwide from TB in 2005.

The developing field of bionanotechnology promises great advances in medicine, particularly in the areas of diagnostics and therapeutics. By collaborating with Oxford Immunotec, BNC is facilitating the development of precise, accurate techniques to diagnose and monitor infection and disease.

####

About Bio Nano Consulting (BNC)
The BNC is a specialist research and development consultancy operating in the convergent field of bionanotechnology. A joint venture of Imperial College London and University College London, the BNC is funded through the Technology Strategy Board (TSB) with additional support from the London Development Agency (LDA).

Along with its partner organisation, the National Physical Laboratory (NPL), the BNC offers a service to the biomedical and healthcare industries in microsystems and nanotechnology. This encompasses design, 3-D modelling and visualisation, rapid prototyping, and characterisation.

About Oxford Immunotec
Oxford Immunotec, the T cell measurement company is based in Oxford, UK and Marlborough, MA. The Company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells. T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

T-SPOT® is a trademark of Oxford Immunotec.

For more information please see: www.oxfordimmunotec.com

For more information, please click here

Contacts:
Product Enquiries
Bio Nano Consulting
Dr David Sarphie – CEO
t: +44 (0)207 268 3032

Media enquiries
Alto Marketing Limited
Neil Ravenhill
t: +44 (0)1489 557672

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: